Valuation: BIOLASE, Inc.

Chart: BIOLASE, Inc.

27/25/27	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/25/19	EnVVeno Medical Names Jennifer Bright CFO	MT
05/25/05	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/25/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/25/21	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/25/18	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/25/14	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/25/29	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/25/14	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/25/13	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/25/08	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/24/23	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/24/15	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/24/01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/23/31	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/23/20	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/22/20	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/25/14	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/24/08	Biolase: Q3 Earnings Snapshot	AQ
08/24/08	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
02/24/02	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
09/24/09	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Martha Somerman BRD	Director/Board Member	-	16/08/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/09/23	Goldman Sachs & Co. LLC (Private Banking)	Other	Company	1,44,501	13.8444%
08/06/23	Kathleen O'Loughlin	Free	Director	5,02,404	1.6050%
08/06/23	Martha Somerman	Free	Director	5,18,429	1.6562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	0.00%	0.00%	-	-	36
BOXABL INC.	-19.76%	-50.81%	-60.24%	-	1.26TCr
FREENOME, INC.	+1.25%	-12.53%	+7.46%	-	121.55Cr
CHURCHILL CAPITAL CORP XI	+5.83%	-2.09%	-	-	81Cr
CENTIEL AG	-6.55%	-6.73%	+265.27%	-68.88%	66Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.05%	+0.30%	-	-	64Cr
CHURCHILL CAPITAL CORP XII	-0.93%	-1.84%	-	-	61Cr
BAIN CAPITAL GSS INVESTMENT CORP.	+0.19%	+0.54%	-	-	60Cr
DEEP FISSION, INC.	+1.02%	-9.93%	-	-	60Cr
Average	-2.10%	-8.27%	+70.83%	-68.88%	196.93Cr
Weighted average by Cap.	-13.93%	-37.37%	-39.82%	-68.88%

	2022	2023
Net sales	4.85Cr 4.25Cr 3.96Cr 3.64Cr 6.83Cr 462.99Cr 6.95Cr 47Cr 18Cr 229.61Cr 18Cr 18Cr 793.31Cr	4.92Cr 4.31Cr 4.02Cr 3.7Cr 6.93Cr 469.69Cr 7.05Cr 48Cr 19Cr 232.94Cr 18Cr 18Cr 804.8Cr
Net income	-2.86Cr -2.51Cr -2.34Cr -2.15Cr -4.03Cr -273.56Cr -4.1Cr -28Cr -11Cr -135.67Cr -11Cr -11Cr -468.73Cr	-2.06Cr -1.81Cr -1.69Cr -1.55Cr -2.91Cr -197.11Cr -2.96Cr -20Cr -7.83Cr -98Cr -7.75Cr -7.58Cr -337.74Cr
Net Debt	1.15Cr 1.01Cr 94.04L 86.49L 1.62Cr 109.93Cr 1.65Cr 11Cr 4.37Cr 55Cr 4.32Cr 4.23Cr 188.37Cr	91.41L 80.22L 74.7L 68.71L 1.29Cr 87Cr 1.31Cr 8.86Cr 3.47Cr 43Cr 3.43Cr 3.36Cr 149.64Cr